Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 34, 2014, Pages 12468-12473

  Sundberg, Thomas B ^a   Choi, Hwan Geun ^b,c   Song, Joo Hye ^d   Russell, Caitlin N ^d   Hussain, Mahmud M ^a,e,f   Graham, Daniel B ^a   Khor, Bernard ^d   Gagnon, John ^a   O'Connell, Daniel J ^a   Narayan, Kavitha ^a   Dancǐ́k, Vlado ^a   Perez, Jose R ^a   Reinecker, Hans Christian ^d   Gray, Nathanael S ^b,c   Schreiber, Stuart L ^a,e,f   Xavier, Ramnik J ^a,d   Shamji, Alykhan F ^a  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD UNIVERSITY   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BOSUTINIB; CHEMOKINE RECEPTOR CX3CR1; DASATINIB; GLYCOPROTEIN P 15095; HG 9 91 01; IMATINIB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN KINASE P60; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SALT INDUCIBLE KINASE; SARACATINIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; AUTACOID; CARBANILAMIDE DERIVATIVE; CREB1 PROTEIN, MOUSE; CRTC3 PROTEIN, MOUSE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKINE; HG-9-91-01; IL10 PROTEIN, MOUSE; NITRILE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SALT-INDUCIBLE KINASE-2, MOUSE; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CYTOKINE PRODUCTION; DENDRITIC CELL; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOREGULATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; YEAST CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; METABOLISM; SIGNAL TRANSDUCTION; SMALL INTESTINE; TRANSGENIC MOUSE;

ANILINE COMPOUNDS; ANIMALS; CELLS, CULTURED; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYTOKINES; DENDRITIC CELLS; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTESTINE, SMALL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELOID CELLS; NITRILES; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; QUINOLINES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; THIAZOLES; TRANSCRIPTION FACTORS;

EID: 84906707276     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1412308111     Document Type: Article

References (36)

1. Khor B, Gardet A, Xavier RJ (2011) Genetics and pathogenesis of inflammatory bowel disease. Nature 474(7351):307-317.
2. Jostins L, et al.; International IBD Genetics Consortium (IIBDGC) (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491(7422):119-124.
3. Shouval DS, et al. (2014) Interleukin 10 receptor signaling: Master regulator of intestinal mucosal homeostasis in mice and humans. Adv Immunol 122:177-210.
4. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75(2):263-274.
5. Spencer SD, et al. (1998) The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 187(4):571-578. (Pubitemid 28093359)
6. Tomoyose M, Mitsuyama K, Ishida H, Toyonaga A, Tanikawa K (1998) Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis. Scand J Gastroenterol 33(4):435-440. (Pubitemid 28212558)
7. Schreiber S, et al. (2000) Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119(6):1461-1472. (Pubitemid 32198671)
8. Marlow GJ, van Gent D, Ferguson LR (2013) Why interleukin-10 supplementation does not work in Crohn's disease patients. World J Gastroenterol 19(25):3931-3941.
9. Braat H, et al. (2006) A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn' s disease. Clin Gastroenterol Hepatol 4(6):754-759. (Pubitemid 43841860)
10. Wynn TA, Chawla A, Pollard JW (2013) Macrophage biology in development, homeostasis and disease. Nature 496(7446):445-455.
11. Grimm MC, et al. (1995) Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J Gastroenterol Hepatol 10(4):387-395.
12. Zigmond E, et al. (2012) Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity 37(6):1076-1090.
13. Zigmond E, Jung S (2013) Intestinal macrophages: Well educated exceptions from the rule. Trends Immunol 34(4):162-168.
14. Niess JH, et al. (2005) CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307(5707):254-258. (Pubitemid 40116240)
15. Kayama H, et al. (2012) Intestinal CX3C chemokine receptor 1(high) (CX3CR1(high)) myeloid cells prevent T-cell-dependent colitis. Proc Natl Acad Sci USA 109(13):5010-5015.
16. Saraiva M, O'Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10(3):170-181.
17. Martin M, Rehani K, Jope RS, Michalek SM (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6(8):777-784. (Pubitemid 43090463)
18. Matsumoto T, et al. (2013) Protein kinase C inhibitor generates stable human tolerogenic dendritic cells. J Immunol 191(5):2247-2257.
19. Rodríguez M, et al. (2014) Polarization of the innate immune response by prostaglandin E2: A puzzle of receptors and signals. Mol Pharmacol 85(1):187-197.
20. MacKenzie KF, et al. (2013) PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J Immunol 190(2):565-577.
21. Clark K, et al. (2012) Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci USA 109(42):16986-16991.
22. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7(5):345-356. (Pubitemid 46652483)
23. Davis MI, et al. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29(11):1046-1051.
24. Maynard CL, et al. (2007) Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat Immunol 8(9):931-941. (Pubitemid 47300007)
25. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057-1061. (Pubitemid 36222930)
26. Pot C, Apetoh L, Kuchroo VK (2011) Type 1 regulatory T cells (Tr1) in autoimmunity. Semin Immunol 23(3):202-208.
27. Fraser CK, et al. (2009) Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. Exp Hematol 37(12):1435-1444.
28. Kantarjian H, et al. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362(24):2260-2270.
29. Yang Y, et al. (2012) Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 120(23):4533-4543.
30. Ghoreschi K, et al. (2010) Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature 467(7318):967-971.
31. Cross RK, Wilson KT (2003) Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis 9(3):179-189. (Pubitemid 36592449)
32. Bos JL (2006) Epac proteins: Multi-purpose cAMP targets. Trends Biochem Sci 31(12):680-686.
33. Liu JZ, et al.; UK-PSCSC Consortium; International IBD Genetics Consortium; International PSC Study Group (2013) Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 45(6):670-675.
34. Hartmann G, et al. (2000) Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 292(1):22-30. (Pubitemid 30026352)
35. 2 receptor subtype 4 agonist. J Pharmacol Exp Ther 341(2):340-349.
36. Houslay MD, Schafer P, Zhang KY (2005) Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10(22):1503-1519. (Pubitemid 41527193)